These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
534 related items for PubMed ID: 2182263
21. [Knowledge about metabolic capacity is important in drug therapy]. Alván G, Dahl ML. Lakartidningen; 1992 Feb 05; 89(6):382, 387-90. PubMed ID: 1738265 [Abstract] [Full Text] [Related]
25. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. II. Participation of CYP isoenzymes in the metabolism of endogenous substances and drugs. Tomaszewski P, Kubiak-Tomaszewska G, Pachecka J. Acta Pol Pharm; 2008 Feb 05; 65(3):307-18. PubMed ID: 18646550 [Abstract] [Full Text] [Related]
26. Effects of water deprivation on drug pharmacokinetics: correlation between drug metabolism and hepatic CYP isozymes. Lee JH, Oh JM, Lee MG. Arch Pharm Res; 2008 Aug 05; 31(8):951-64. PubMed ID: 18787780 [Abstract] [Full Text] [Related]
28. Update: genetic polymorphism of drug metabolizing enzymes in humans. Tanaka E. J Clin Pharm Ther; 1999 Oct 05; 24(5):323-9. PubMed ID: 10583694 [Abstract] [Full Text] [Related]
29. [Cytochrome p450 and their implication in chemotherapy]. Delwaide PA. Rev Med Liege; 1998 Nov 05; 53(11):700-10. PubMed ID: 9887664 [Abstract] [Full Text] [Related]
30. Polymorphism of cytochrome P450 and xenobiotic toxicity. Ingelman-Sundberg M. Toxicology; 2002 Dec 27; 181-182():447-52. PubMed ID: 12505350 [Abstract] [Full Text] [Related]
31. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Tyndale RF, Sunahara R, Inaba T, Kalow W, Gonzalez FJ, Niznik HB. Mol Pharmacol; 1991 Jul 27; 40(1):63-8. PubMed ID: 1857341 [Abstract] [Full Text] [Related]
33. Characterization of intestinal and hepatic P450 enzymes in cynomolgus monkeys with typical substrates and inhibitors for human P450 enzymes. Yoda N, Emoto C, Date S, Kondo S, Miyake M, Nakazato S, Umehara K, Kashiyama E. Xenobiotica; 2012 Aug 27; 42(8):719-30. PubMed ID: 22324396 [Abstract] [Full Text] [Related]
35. Polymorphic oxidation of debrisoquine and sparteine. Eichelbaum M. Prog Clin Biol Res; 1986 Aug 27; 214():157-67. PubMed ID: 3523506 [No Abstract] [Full Text] [Related]
36. Chimeric mice with humanized liver. Katoh M, Tateno C, Yoshizato K, Yokoi T. Toxicology; 2008 Apr 03; 246(1):9-17. PubMed ID: 18248870 [Abstract] [Full Text] [Related]
37. Cytochrome P450 genetic polymorphism in neonatal drug metabolism: role and practical consequences towards a new drug culture in neonatology. Fanni D, Ambu R, Gerosa C, Nemolato S, Castagnola M, Van Eyken P, Faa G, Fanos V. Int J Immunopathol Pharmacol; 2014 Apr 03; 27(1):5-13. PubMed ID: 24674673 [Abstract] [Full Text] [Related]
39. Cytochrome P450 enzymes: ubiquitous "receptors" for drugs. LaBella FS. Can J Physiol Pharmacol; 1991 Aug 03; 69(8):1129-32. PubMed ID: 1664291 [Abstract] [Full Text] [Related]
40. Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility. Smith CA, Moss JE, Gough AC, Spurr NK, Wolf CR. Environ Health Perspect; 1992 Nov 03; 98():107-12. PubMed ID: 1486838 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]